Royalties--Rates | NAVB Message Board Posts

Navidea Biopharmaceuticals, Inc.

  NAVB website

NAVB   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  32916 of 33103  at  9/27/2020 12:14:35 PM  by

z3peru

The following message was updated on 9/27/2020 12:25:06 PM.

 In response to msg 32911 by  z3peru
view thread

Re: Royalties--Rates

  
  
 I said it is speculated that royalty rates are 10-20%.  Let's flesh that out a bit.
 
One source says pharmaceutical royalties range from 8-18%.  It matters as to where the product is in the regulatory approval process--preclinical, Phase I, Phase II, Phase III, pending approval, approved.  One source says a product in Phase III receives on average a 14.1% royalty.  Is it possible that the delay of signing the deal with Jubilant is related to starting Phase III and obtaining a higher royalty rate? 
 
If the range is 8-18%, possibly (but not necessarily) the average rate is 13%.  Presumably a therapeutic is going to command a higher rate than a diagnostic. Jed said in the 2nd Qtr conference call that they had agreed to "an above average royalty rate."  
 
So what rate should we use in figuring out top line revenues to NAVB?  IMO 12% on the low side and 15% on the high side.   
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 329
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
32921 Re: Royalties--Rates LotBMan 1 9/28/2020 11:09:57 AM






Financial Market Data provided by
.
Loading...